{"paper_id":"235f502d-c032-4918-9e74-1102900a59f4","body_text":"Development and validation of a functional ex vivo paclitaxel and eribulin sensitivity assay for breast cancer, the REMIT assay | Research Square window.SnipcartSettings = { analytics: { enabled: false } }; (function() { var accessVector = localStorage.getItem('access_vector') || ''; window.dataLayer = window.dataLayer || []; if (accessVector) { window.dataLayer.push({ user: { profile: { profileInfo: { snid: accessVector } } } }); } })(); (function(w,d,s,l,i){w[l]=w[l]||[];w[l].push({'gtm.start':new Date().getTime(),event:'gtm.js'});var f=d.getElementsByTagName(s)[0],j=d.createElement(s),dl=l!='dataLayer'?'&l='+l:'';j.async=true;j.src='https://www.googletagmanager.com/gtm.js?id='+i+dl;f.parentNode.insertBefore(j,f);})(window,document,'script','dataLayer','GTM-K279D39R'); Browse Preprints In Review Journals COVID-19 Preprints AJE Video Bytes Research Tools Research Promotion AJE Professional Editing AJE Rubriq About Preprint Platform In Review Editorial Policies Our Team Advisory Board Help Center Sign In Submit a Preprint Cite Share Download PDF Article Development and validation of a functional ex vivo paclitaxel and eribulin sensitivity assay for breast cancer, the REMIT assay Dik van Gent, Zofia Komar, Nicole Verkaik, Ahmed Dahmani, Elodie Montaudon, and 4 more This is a preprint; it has not been peer reviewed by a journal. https://doi.org/ 10.21203/rs.3.rs-4873503/v1 This work is licensed under a CC BY 4.0 License Status: Published Journal Publication published 17 Feb, 2025 Read the published version in npj Breast Cancer → Version 1 posted 10 You are reading this latest preprint version Abstract Breast cancer is the most common cancer amongst women worldwide, however clinically validated chemotherapy response biomarkers that can accurately predict treatment response in patients are largely lacking. Therefore, in this study, functional paclitaxel and eribulin ex vivo sensitivity assays were developed. Patient derived xenograft (PDX) models were used to compare the ex vivo predicted treatment outcome with the sensitivity of mice in vivo. We validated the previously developed sensitivity assay for paclitaxel, which is based on the ratio between replicating (EdU) and mitotic (phospho-Histone H3; pH3) cells as a proxy for blocked mitosis. The assay showed 90% correlation between the ex vivo and in vivo response to paclitaxel treatment in the PDX models. We propose the term REMIT (REplication MITosis) assay and show that it is also a suitable test to predict eribulin sensitivity. The reproducibility of the REMIT assay for paclitaxel and eribulin was determined to be 80% and 83%, respectively. These results justify further clinical validation of the REMIT assay in breast cancer patients. Biological sciences/Cancer/Breast cancer Biological sciences/Cancer/Tumour biomarkers Biological sciences/Cell biology/Cytoskeleton taxanes chemotherapy functional biomarker tumor tissue slices predictive assay Full Text Additional Declarations (Not answered) Supplementary Files Supplementarydata.pdf Cite Share Download PDF Status: Published Journal Publication published 17 Feb, 2025 Read the published version in npj Breast Cancer → Version 1 posted Editorial decision: revise 23 Oct, 2024 Review # 2 received at journal 07 Oct, 2024 Reviewer # 2 agreed at journal 17 Sep, 2024 Review # 1 received at journal 07 Sep, 2024 Reviewer # 1 agreed at journal 22 Aug, 2024 Reviewers invited by journal 20 Aug, 2024 Editor assigned by journal 19 Aug, 2024 Submission checks completed at journal 16 Aug, 2024 First submitted to journal 12 Aug, 2024 Unknown event 09 Aug, 2024 You are reading this latest preprint version Research Square lets you share your work early, gain feedback from the community, and start making changes to your manuscript prior to peer review in a journal. As a division of Research Square Company, we’re committed to making research communication faster, fairer, and more useful. We do this by developing innovative software and high quality services for the global research community. Our growing team is made up of researchers and industry professionals working together to solve the most critical problems facing scientific publishing. Also discoverable on Platform About Our Team In Review Editorial Policies Advisory Board Help Center Resources Author Services Accessibility API Access RSS feed Manage Cookie Preferences © Research Square 2026 | ISSN 2693-5015 (online) Privacy Policy Terms of Service Do Not Sell My Personal Information {\"props\":{\"pageProps\":{\"initialData\":{\"identity\":\"rs-4873503\",\"acceptedTermsAndConditions\":true,\"allowDirectSubmit\":false,\"archivedVersions\":[],\"articleType\":\"Article\",\"associatedPublications\":[],\"authors\":[{\"id\":342694639,\"identity\":\"1c7ee856-5f3b-4b3a-8b9d-1aaffdb638bc\",\"order_by\":0,\"name\":\"Dik van Gent\",\"email\":\"data:image/png;base64,iVBORw0KGgoAAAANSUhEUgAAAZAAAAAyAQMAAABI0h/eAAAABlBMVEX///8AAABVwtN+AAAACXBIWXMAAA7EAAAOxAGVKw4bAAAA7UlEQVRIiWNgGAWjYDCCAzAGewOycAERWnh4DiALGxCjRSKBSC18B3gMPxf8ssmzl3x87MOPP9sS5087/IC5AI8WyQM8xtIz+9KKeaTTkmf2tt1O3HA7zYB5Bh4tBgfYEqR5ew4n9kjnGDPwNgC1SOcwMPPg15L8m7fnf2KP5PnPjH/+3E6cP5ugFuZj0jw/DiT2SPAwM/Ow3U5suE1Ai+Rh5mPWvA3JiT1n0oyZZdtuG4P8chifFr7jjc23ef7YJba3H37M+ObPbdn5s5MfPuapwK2FgRmIGdvQBA/g0QAFfwgrGQWjYBSMghEMABzkUglNQVo8AAAAAElFTkSuQmCC\",\"orcid\":\"https://orcid.org/0000-0003-1473-8148\",\"institution\":\"Erasmus MC Cancer Institute\",\"correspondingAuthor\":true,\"prefix\":\"\",\"firstName\":\"Dik\",\"middleName\":\"van\",\"lastName\":\"Gent\",\"suffix\":\"\"},{\"id\":342694640,\"identity\":\"b378029b-a9c8-47af-8a5c-56b775201136\",\"order_by\":1,\"name\":\"Zofia Komar\",\"email\":\"\",\"orcid\":\"\",\"institution\":\"Erasmus MC\",\"correspondingAuthor\":false,\"prefix\":\"\",\"firstName\":\"Zofia\",\"middleName\":\"\",\"lastName\":\"Komar\",\"suffix\":\"\"},{\"id\":342694641,\"identity\":\"4489e787-42db-4dbb-9564-748d99a30482\",\"order_by\":2,\"name\":\"Nicole Verkaik\",\"email\":\"\",\"orcid\":\"\",\"institution\":\"Erasmus MC Cancer Institute\",\"correspondingAuthor\":false,\"prefix\":\"\",\"firstName\":\"Nicole\",\"middleName\":\"\",\"lastName\":\"Verkaik\",\"suffix\":\"\"},{\"id\":342694642,\"identity\":\"5a7ca675-b005-45f3-a8d8-f0a71737b7f8\",\"order_by\":3,\"name\":\"Ahmed Dahmani\",\"email\":\"\",\"orcid\":\"\",\"institution\":\"Institut Curie\",\"correspondingAuthor\":false,\"prefix\":\"\",\"firstName\":\"Ahmed\",\"middleName\":\"\",\"lastName\":\"Dahmani\",\"suffix\":\"\"},{\"id\":342694643,\"identity\":\"add11e91-68de-42c3-8afd-83932afe54de\",\"order_by\":4,\"name\":\"Elodie Montaudon\",\"email\":\"\",\"orcid\":\"\",\"institution\":\"Institut Curie\",\"correspondingAuthor\":false,\"prefix\":\"\",\"firstName\":\"Elodie\",\"middleName\":\"\",\"lastName\":\"Montaudon\",\"suffix\":\"\"},{\"id\":342694644,\"identity\":\"f8f18cb2-43bf-4431-975c-cc719d5fe1ec\",\"order_by\":5,\"name\":\"Roland Kanaar\",\"email\":\"\",\"orcid\":\"\",\"institution\":\"Erasmus MC Cancer Institute\",\"correspondingAuthor\":false,\"prefix\":\"\",\"firstName\":\"Roland\",\"middleName\":\"\",\"lastName\":\"Kanaar\",\"suffix\":\"\"},{\"id\":342694645,\"identity\":\"8f5bf3b3-df1e-42e5-94ed-a799f41989fb\",\"order_by\":6,\"name\":\"Adriaan Houtsmuller\",\"email\":\"\",\"orcid\":\"\",\"institution\":\"Erasmus MC\",\"correspondingAuthor\":false,\"prefix\":\"\",\"firstName\":\"Adriaan\",\"middleName\":\"\",\"lastName\":\"Houtsmuller\",\"suffix\":\"\"},{\"id\":342694646,\"identity\":\"be2a93bc-9950-4da8-bd1e-1ffbd92e67e0\",\"order_by\":7,\"name\":\"Agnes Jager\",\"email\":\"\",\"orcid\":\"https://orcid.org/0000-0002-7713-1450\",\"institution\":\"Erasmus MC Cancer Institute\",\"correspondingAuthor\":false,\"prefix\":\"\",\"firstName\":\"Agnes\",\"middleName\":\"\",\"lastName\":\"Jager\",\"suffix\":\"\"},{\"id\":342694647,\"identity\":\"bff7878e-ebc5-476d-b9f5-f0411a1734da\",\"order_by\":8,\"name\":\"Elisabetta Marangoni\",\"email\":\"\",\"orcid\":\"https://orcid.org/0000-0002-3337-6448\",\"institution\":\"Inst.Curie\",\"correspondingAuthor\":false,\"prefix\":\"\",\"firstName\":\"Elisabetta\",\"middleName\":\"\",\"lastName\":\"Marangoni\",\"suffix\":\"\"}],\"badges\":[],\"createdAt\":\"2024-08-07 09:21:39\",\"currentVersionCode\":1,\"declarations\":\"\",\"doi\":\"10.21203/rs.3.rs-4873503/v1\",\"doiUrl\":\"https://doi.org/10.21203/rs.3.rs-4873503/v1\",\"draftVersion\":[],\"editorialEvents\":[{\"content\":\"https://doi.org/10.1038/s41523-025-00734-x\",\"type\":\"published\",\"date\":\"2025-02-17T05:00:00+00:00\"}],\"editorialNote\":\"\",\"failedWorkflow\":false,\"files\":[{\"id\":76674876,\"identity\":\"6b2768e1-cc67-4225-ba72-6a0850a09202\",\"added_by\":\"auto\",\"created_at\":\"2025-02-19 14:18:04\",\"extension\":\"pdf\",\"order_by\":1,\"title\":\"\",\"display\":\"\",\"copyAsset\":false,\"role\":\"manuscript-pdf\",\"size\":1613260,\"visible\":true,\"origin\":\"\",\"legend\":\"Article File\",\"description\":\"\",\"filename\":\"KomarNPJtextandfigurescombinednew.pdf\",\"url\":\"https://assets-eu.researchsquare.com/files/rs-4873503/v1_covered_ebd5e3d9-a0bc-4988-9596-917307d90746.pdf\"},{\"id\":64728261,\"identity\":\"5a4eb06b-b79b-4540-a326-d1f374693ee5\",\"added_by\":\"auto\",\"created_at\":\"2024-09-18 06:15:11\",\"extension\":\"pdf\",\"order_by\":1,\"title\":\"\",\"display\":\"\",\"copyAsset\":false,\"role\":\"supplement\",\"size\":1341116,\"visible\":true,\"origin\":\"\",\"legend\":\"\\u003cp\\u003e\\u003cbr\\u003e\\u003c/p\\u003e\",\"description\":\"\",\"filename\":\"Supplementarydata.pdf\",\"url\":\"https://assets-eu.researchsquare.com/files/rs-4873503/v1/5a1fb5435ee93526bdb2a960.pdf\"}],\"financialInterests\":\"(Not answered)\",\"formattedTitle\":\"Development and validation of a functional ex vivo paclitaxel and eribulin sensitivity assay for breast cancer, the REMIT assay\",\"fulltext\":[],\"fulltextSource\":\"\",\"fullText\":\"\",\"funders\":[],\"hasAdminPriorityOnWorkflow\":false,\"hasManuscriptDocX\":false,\"hasOptedInToPreprint\":true,\"hasPassedJournalQc\":\"\",\"hasAnyPriority\":false,\"hideJournal\":false,\"highlight\":\"\",\"institution\":\"\",\"isAcceptedByJournal\":true,\"isAuthorSuppliedPdf\":true,\"isDeskRejected\":\"\",\"isHiddenFromSearch\":false,\"isInQc\":false,\"isInWorkflow\":false,\"isPdf\":true,\"isPdfUpToDate\":true,\"isWithdrawnOrRetracted\":false,\"journal\":{\"display\":true,\"email\":\"info@researchsquare.com\",\"identity\":\"npj-breast-cancer\",\"isNatureJournal\":false,\"hasQc\":false,\"allowDirectSubmit\":false,\"externalIdentity\":\"npjbcancer\",\"sideBox\":\"Learn more about [npj Breast Cancer](http://www.nature.com/npjbcancer/)\",\"snPcode\":\"41523\",\"submissionUrl\":\"https://mts-npjbcancer.nature.com/\",\"title\":\"npj Breast Cancer\",\"twitterHandle\":\"\",\"acdcEnabled\":true,\"dfaEnabled\":true,\"editorialSystem\":\"ejp\",\"reportingPortfolio\":\"NPJ\",\"inReviewEnabled\":true,\"inReviewRevisionsEnabled\":true},\"keywords\":\"taxanes, chemotherapy, functional biomarker, tumor tissue slices, predictive assay\",\"lastPublishedDoi\":\"10.21203/rs.3.rs-4873503/v1\",\"lastPublishedDoiUrl\":\"https://doi.org/10.21203/rs.3.rs-4873503/v1\",\"license\":{\"name\":\"CC BY 4.0\",\"url\":\"https://creativecommons.org/licenses/by/4.0/\"},\"manuscriptAbstract\":\"Breast cancer is the most common cancer amongst women worldwide, however clinically validated chemotherapy response biomarkers that can accurately predict treatment response in patients are largely lacking. Therefore, in this study, functional paclitaxel and eribulin ex vivo sensitivity assays were developed. Patient derived xenograft (PDX) models were used to compare the ex vivo predicted treatment outcome with the sensitivity of mice in vivo. We validated the previously developed sensitivity assay for paclitaxel, which is based on the ratio between replicating (EdU) and mitotic (phospho-Histone H3; pH3) cells as a proxy for blocked mitosis. The assay showed 90% correlation between the ex vivo and in vivo response to paclitaxel treatment in the PDX models. We propose the term REMIT (REplication MITosis) assay and show that it is also a suitable test to predict eribulin sensitivity. The reproducibility of the REMIT assay for paclitaxel and eribulin was determined to be 80% and 83%, respectively. These results justify further clinical validation of the REMIT assay in breast cancer patients.\",\"manuscriptTitle\":\"Development and validation of a functional ex vivo paclitaxel and eribulin sensitivity assay for breast cancer, the REMIT assay\",\"msid\":\"\",\"msnumber\":\"\",\"nonDraftVersions\":[{\"code\":1,\"date\":\"2024-09-18 06:15:06\",\"doi\":\"10.21203/rs.3.rs-4873503/v1\",\"editorialEvents\":[{\"type\":\"communityComments\",\"content\":0},{\"type\":\"decision\",\"content\":\"revise\",\"date\":\"2024-10-23T12:57:22+00:00\",\"index\":\"\",\"fulltext\":\"\"},{\"type\":\"editorInvitedReview\",\"content\":\"This content is not available.\",\"date\":\"2024-10-07T13:39:29+00:00\",\"index\":2,\"fulltext\":\"This content is not available.\"},{\"type\":\"reviewerAgreed\",\"content\":\"This content is not available.\",\"date\":\"2024-09-17T13:15:46+00:00\",\"index\":2,\"fulltext\":\"This content is not available.\"},{\"type\":\"editorInvitedReview\",\"content\":\"This content is not available.\",\"date\":\"2024-09-07T22:36:50+00:00\",\"index\":1,\"fulltext\":\"This content is not available.\"},{\"type\":\"reviewerAgreed\",\"content\":\"This content is not available.\",\"date\":\"2024-08-22T08:24:52+00:00\",\"index\":1,\"fulltext\":\"This content is not available.\"},{\"type\":\"reviewersInvited\",\"content\":\"\",\"date\":\"2024-08-20T13:18:35+00:00\",\"index\":\"\",\"fulltext\":\"\"},{\"type\":\"editorAssigned\",\"content\":\"\",\"date\":\"2024-08-19T11:44:04+00:00\",\"index\":\"\",\"fulltext\":\"\"},{\"type\":\"checksComplete\",\"content\":\"\",\"date\":\"2024-08-16T07:00:24+00:00\",\"index\":\"\",\"fulltext\":\"\"},{\"type\":\"submitted\",\"content\":\"npj Breast Cancer\",\"date\":\"2024-08-12T07:36:46+00:00\",\"index\":\"\",\"fulltext\":\"\"},{\"type\":\"checksFailed\",\"content\":\"\",\"date\":\"2024-08-09T10:34:20+00:00\",\"index\":\"\",\"fulltext\":\"\"}],\"status\":\"published\",\"journal\":{\"display\":true,\"email\":\"info@researchsquare.com\",\"identity\":\"npj-breast-cancer\",\"isNatureJournal\":false,\"hasQc\":false,\"allowDirectSubmit\":false,\"externalIdentity\":\"npjbcancer\",\"sideBox\":\"Learn more about [npj Breast Cancer](http://www.nature.com/npjbcancer/)\",\"snPcode\":\"41523\",\"submissionUrl\":\"https://mts-npjbcancer.nature.com/\",\"title\":\"npj Breast Cancer\",\"twitterHandle\":\"\",\"acdcEnabled\":true,\"dfaEnabled\":true,\"editorialSystem\":\"ejp\",\"reportingPortfolio\":\"NPJ\",\"inReviewEnabled\":true,\"inReviewRevisionsEnabled\":true}}],\"origin\":\"\",\"ownerIdentity\":\"bffc4466-e4c5-42f0-a3d1-4cef057919ff\",\"owner\":[],\"postedDate\":\"September 18th, 2024\",\"published\":true,\"recentEditorialEvents\":[],\"rejectedJournal\":[],\"revision\":\"\",\"amendment\":\"\",\"status\":\"published-in-journal\",\"subjectAreas\":[{\"id\":36306155,\"name\":\"Biological sciences/Cancer/Breast cancer\"},{\"id\":36306156,\"name\":\"Biological sciences/Cancer/Tumour biomarkers\"},{\"id\":36306157,\"name\":\"Biological sciences/Cell biology/Cytoskeleton\"}],\"tags\":[],\"updatedAt\":\"2025-02-19T14:17:16+00:00\",\"versionOfRecord\":{\"articleIdentity\":\"rs-4873503\",\"link\":\"https://doi.org/10.1038/s41523-025-00734-x\",\"journal\":{\"identity\":\"npj-breast-cancer\",\"isVorOnly\":false,\"title\":\"npj Breast Cancer\"},\"publishedOn\":\"2025-02-17 05:00:00\",\"publishedOnDateReadable\":\"February 17th, 2025\"},\"versionCreatedAt\":\"2024-09-18 06:15:06\",\"video\":\"\",\"vorDoi\":\"10.1038/s41523-025-00734-x\",\"vorDoiUrl\":\"https://doi.org/10.1038/s41523-025-00734-x\",\"workflowStages\":[]},\"version\":\"v1\",\"identity\":\"rs-4873503\",\"journalConfig\":\"researchsquare\"},\"__N_SSP\":true},\"page\":\"/article/[identity]/[[...version]]\",\"query\":{\"redirect\":\"/article/rs-4873503\",\"identity\":\"rs-4873503\",\"version\":[\"v1\"]},\"buildId\":\"qtupq5eGEP_6zYnWcrvyt\",\"isFallback\":false,\"isExperimentalCompile\":false,\"dynamicIds\":[84888],\"gssp\":true,\"scriptLoader\":[]}","source_license":"CC-BY-4.0","license_restricted":false}